Alphatec (NASDAQ:ATEC) EVP Craig Hunsaker Sells 82,765 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig Hunsaker sold 82,765 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the transaction, the executive vice president directly owned 1,726,209 shares in the company, valued at $21,491,302.05. This trade represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Alphatec Trading Down 2.8%

NASDAQ:ATEC opened at $12.51 on Wednesday. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. Alphatec Holdings, Inc. has a one year low of $8.81 and a one year high of $23.29. The company has a market cap of $1.89 billion, a PE ratio of -13.17 and a beta of 1.02. The firm has a 50-day moving average of $15.61 and a 200-day moving average of $16.96.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. Alphatec’s revenue was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.23) EPS. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of Alphatec

Several hedge funds have recently made changes to their positions in ATEC. Vanguard Group Inc. raised its stake in Alphatec by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock valued at $99,091,000 after acquiring an additional 158,295 shares during the period. Assenagon Asset Management S.A. boosted its stake in Alphatec by 7,083.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company’s stock worth $10,911,000 after purchasing an additional 739,982 shares during the period. Lisanti Capital Growth LLC purchased a new position in Alphatec during the third quarter valued at approximately $3,305,000. American Century Companies Inc. increased its holdings in shares of Alphatec by 6.0% in the second quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company’s stock worth $68,567,000 after purchasing an additional 347,130 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Alphatec during the third quarter worth about $1,115,000. 66.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ATEC has been the subject of several recent research reports. TD Cowen reiterated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Piper Sandler restated an “overweight” rating on shares of Alphatec in a research note on Wednesday, February 25th. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Alphatec in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Finally, Stifel Nicolaus cut their price target on shares of Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Monday. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and an average price target of $22.82.

Key Stories Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Quarterly results and analyst support: Alphatec beat Q4 EPS estimates and reported +20% revenue growth year‑over‑year (Feb. 24), and multiple firms maintain buy ratings; consensus price target remains materially above the current price (~$22.82). MarketBeat Coverage
• Positive Sentiment: Institutional accumulation: Several large funds (Millennium, Morgan Stanley, Tudor, Granite) materially increased stakes over recent quarters, signaling confidence from hedge funds/asset managers. Institutional Trading Details
• Neutral Sentiment: Analyst price‑target change: Stifel lowered its target from $24 to $20 but retained a Buy rating — still optimistic but less aggressive on upside. Benzinga Article
• Neutral Sentiment: Short interest postings show 0 shares / NaN changes for early March — likely a data or reporting quirk rather than a true change in short positioning; not meaningful by itself. (March 9–10 updates)
• Negative Sentiment: Insider selling by senior executives: General Counsel Tyson Eliot Marshall sold 88,835 shares at an average $12.49 (total ~$1.11M) and EVP Craig Hunsaker sold 33,602 and 82,765 shares on March 6 and March 9 (~$410k and ~$1.03M). These disclosures show notable reductions in insider holdings and are commonly viewed as near‑term negative signals. SEC filings: Marshall Form 4 and Hunsaker Form 4

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.